/
SION
$42.97+$0.79 (+1.87%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.9B
45M shares
52-week range
$15.10 – $48.45
84% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.71%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$17.97
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $668.0K | $647.0K |
| Gross profit | $0 | $0 | −$668.0K | −$647.0K |
| Gross margin | — | — | — | — |
| R&D | $34.6M | $40.6M | $57.3M | $60.3M |
| Operating income | −$41.4M | −$50.3M | −$70.6M | −$89.0M |
| EBITDA | −$40.1M | −$46.7M | −$61.0M | −$74.6M |
| Net income | −$40.2M | −$47.3M | −$61.7M | −$75.3M |
| Net margin | — | — | — | — |
| EPS (diluted) | -0.91 | -1.07 | -1.40 | -1.88 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.58 | $-3.16–$-2.17 | 7 |
| 2027 | $3M | $-2.79 | $-3.78–$-2.23 | 7 |
| 2028 | $6M | $-3.20 | $-4.04–$-2.07 | 8 |
| 2029 | $41M | $-2.83 | $-2.83–$-2.83 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.23
Price
$42.97
Implied downside
-97%
Peer comparison
Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
www.sionnatx.com- Employees
- 59
- IPO / List date
- Feb 7, 2025
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds SION.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 14,600 | $429.4K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded SION yet.
